AGM Statement

RNS Number : 8566L
e-Therapeutics plc
09 July 2014
 



 

 

Results of Annual General Meeting

                                                                                     

Oxford and Newcastle, UK, 9 July 2014- e-Therapeutics plc (AIM: ETX), the drug discovery and development company, announces that all resolutions proposed at the Annual General Meeting held today were duly passed.

 

- Ends -

 

e-Therapeutics plc

Steve Medlicott, Finance Director

Tel: +44 (0) 1993 883125

www.etherapeutics.co.uk 

 

N+1 Singer

Aubrey Powell / Jen Boorer

Tel: +44 (0)20 7496 3000

www.n1singer.com 

 

Instinctif Partners

Melanie Toyne-Sewell / Emma Barlow

Tel: +44 (0) 20 7457 2020

Email: e-therapeutics@instinctif.com

 

About e-Therapeutics plc

e-Therapeutics is an AIM-quoted drug discovery and development company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company's discovery and development activity is currently focused in cancer and disorders of the nervous system.


e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company, please visit
www.etherapeutics.co.uk.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMUKORRSAABRAR
UK 100

Latest directors dealings